Inventor · disambiguated record
Chee Meng Low
Also filed as: LOW CHEE M · LOW CHEE MENG
27 granted patents·33 pending applications·234 citations·filing 2002–2025
96Inventor score
Top patents by PatentIndex Score
60 records- 0197US8420098B2Fibronectin based scaffold domain proteins that bind to PCSK9CAMPHAUSEN RAY·Filed 2011·Granted Apr 16, 2013·86 cites·8 claims
- 0295US11692018B2TGF-β polypeptidesCUE BIOPHARMA INC·Filed 2022·Granted Jul 4, 2023·2 cites·23 claims
- 0394US12029782B2MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Granted Jul 9, 2024·1 cites·2 claims
- 0493US12006348B2T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereofCUE BIOPHARMA INC·Filed 2020·Granted Jun 11, 2024·3 cites·8 claims
- 0593US10432752B2Method and system for mobile applications update in the cloudIBM·Filed 2017·Granted Oct 1, 2019·10 cites·12 claims
- 0693US9391996B1Auditable retrieval of privileged credentialsIBM·Filed 2015·Granted Jul 12, 2016·14 cites·1 claims
- 0792US10938954B2Method and system for mobile applications update in the cloudIBM·Filed 2019·Granted Mar 2, 2021·7 cites·20 claims
- 0892US9856309B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 2, 2018·10 cites·16 claims
- 0991US10947297B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Mar 16, 2021·5 cites·19 claims
- 1091US10834084B2Privileged identity authentication based on user behaviorsIBM·Filed 2018·Granted Nov 10, 2020·15 cites·20 claims
- 1190US9234027B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 12, 2016·10 cites·22 claims
- 1290US7620976B2Portable authentication and access control involving multiple identitiesIBM·Filed 2005·Granted Nov 17, 2009·28 cites·40 claims
- 1386US2024239870A1Fibronectin based scaffold domain proteins that bind pcsk9BRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 1484US2025206794A1TGF-Beta PolypeptidesCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1582US10686911B2Method and system for mobile applications update in the cloudIBM·Filed 2018·Granted Jun 16, 2020·2 cites·9 claims
- 1680US2024299515A1Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereofCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1779US10069827B2Extending authentication and authorization capabilities of an application without code changesIBM·Filed 2012·Granted Sep 4, 2018·7 cites·24 claims
- 1879US9088563B2Using service request ticket for multi-factor authenticationIBM·Filed 2013·Granted Jul 21, 2015·5 cites·13 claims
- 1978US9531693B1Auditable retrieval of privileged credentialsIBM·Filed 2016·Granted Dec 27, 2016·2 cites·1 claims
- 2078US2024409606A1T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 2176US11858979B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jan 2, 2024·0 cites·10 claims
- 2275US2023321206A1Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 2374US10769593B2Handling email flows arising from transactions initiated with a shared privileged identity at a service providerIBM·Filed 2017·Granted Sep 8, 2020·2 cites·12 claims
- 2473US8250045B2Non-invasive usage tracking, access control, policy enforcement, audit logging, and user action automation on software applicationsER CHIANG KAI·Filed 2007·Granted Aug 21, 2012·17 cites·19 claims
- 2572US9088562B2Using service request ticket for multi-factor authenticationIBM·Filed 2013·Granted Jul 21, 2015·3 cites·7 claims
- 2669US9917823B2Auditable retrieval of privileged credentialsIBM·Filed 2015·Granted Mar 13, 2018·1 cites·17 claims
- 2769US2025041404A1T Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 2868US2025270284A1MHC Class II Protein ConstructsCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 2967US2024101627A1Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 3066US2024139298A1Mhc class ii t-cell modulatory polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 3166US2025041396A1T Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 3265US2025019411A1T-Cell Engaging Polypeptides and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 3363US9495534B2OCR-based single sign-onIBM·Filed 2013·Granted Nov 15, 2016·1 cites·20 claims
- 3463US2023330197A1Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 3561US2024034770A1T-cell modulatory multimeric polypeptides and methods of use thereofCUE BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 3660US2024197846A1Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3760US2024270815A1Antigen Presenting Polypeptide Complexes and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 3859US10242173B2OCR-based single sign-onIBM·Filed 2018·Granted Mar 26, 2019·0 cites·20 claims
- 3959US2024189403A1Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 4059US2024190933A1Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 4159US2024181025A1Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2022·Application pending·0 cites
- 4258US2023416321A1TGF-Beta PolypeptidesCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4357US2024082411A1T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4457US2023414777A1Antigen Presenting Polypeptide Complexes and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4556US9628483B1Auditable retrieval of privileged credentialsIBM·Filed 2016·Granted Apr 18, 2017·0 cites·1 claims
- 4656US8087070B2Predictive method for multi-party strengthening of authentication credentials with non-real time synchronizationKOH ENG-KIAT·Filed 2005·Granted Dec 27, 2011·3 cites·21 claims
- 4756US2022008467A1T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4856US2023218731A1Antigen Presenting Polypeptide Complexes and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 4956US2022079985A1T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 5056US2021393693A1T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use ThereofCUE BIOPHARMA INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Chee Meng Low files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →